Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 33, 2016
Previous Article Next Article

The Platin-X series: activation, targeting, and delivery

Author affiliations

Abstract

Anticancer platinum (Pt) complexes have long been considered to be one of the biggest success stories in the history of medicinal inorganic chemistry. Yet there remains the hunt for the “magic bullet” which can satisfy the requirements of an effective chemotherapeutic drug formulation. Pt(IV) complexes are kinetically more inert than the Pt(II) congeners and offer the opportunity to append additional functional groups/ligands for prodrug activation, tumor targeting, or drug delivery. The ultimate aim of functionalization is to enhance the tumor selective action and attenuate systemic toxicity of the drugs. Moreover, an increase in cellular accumulation to surmount the resistance of the tumor against the drugs is also of paramount importance in drug development and discovery. In this review, we will address the attempts made in our lab to develop Pt(IV) prodrugs that can be activated and delivered using targeted nanotechnology-based delivery platforms.

Graphical abstract: The Platin-X series: activation, targeting, and delivery

Back to tab navigation

Article information


Submitted
03 May 2016
Accepted
09 Jul 2016
First published
11 Jul 2016

Dalton Trans., 2016,45, 12992-13004
Article type
Perspective

The Platin-X series: activation, targeting, and delivery

U. Basu, B. Banik, R. Wen, R. K. Pathak and S. Dhar, Dalton Trans., 2016, 45, 12992
DOI: 10.1039/C6DT01738J

Social activity

Search articles by author

Spotlight

Advertisements